Skip navigation

DAY ONE TUESDAY, 12 MARCH 2019

8:00

Registration and Continental Breakfast

8:30

Co-Chairs’ Welcome and Opening Remarks

Mike Zhao
Head of Ethics and Compliance, China
UCB

Robert Shropshire
Global Offering Lead
IQVIA

Ethics and Compliance in Business Decision-Making

8:45

PANEL DISCUSSION Building a Culture of Ethics and Integrity to Ensure Corporate Compliance

MODERATOR:

Justus Chua
Head of Legal and Compliance
Boehringer Ingelheim

PANELISTS:

Hussein Al-Shawaf
Compliance & Ethics Manager
Dentsply Sirona

Clarissa Shen
Vice President, China Head of Ethics and Business Integrity
Sanofi

Hiroyuki Fukumori
Director, Corporate Compliance
Taiho Pharmaceutical Co., Ltd.

Kinichi Enomoto
Country Compliance Lead (Japan)
Pfizer Holdings

9:45

Future-Proofing Your China Strategy and Business Operations

Neal Beatty
Partner
Control Risks

10:30

Networking and Refreshment Break

11:00

CASE STUDY Key Indicators to Measure the Value and Performance of a
Compliance Program

Christine Ng
Head, Ethics & Compliance Officer, Greater China
GlaxoSmithKline

11:45

Asia Pacific Life Sciences and Compliance Survey 2018

Yvonne Wu
Deloitte China Life Sciences and Health Care Leader
Deloitte

12:30

Networking Luncheon

Anti-Bribery and Anti-Corruption (ABAC)

13:30

Gain Insights from FCPA Investigations and the Changing Landscape of Global Cooperation

Tiffany R. Moseley
Partner
Loeb & Leob

14:15

Global Anti-Corruption Enforcement and Evolving Challenges for
Life Science Organizations in Asia

Eric Carlson
Partner
Covington & Burling LLP

15:00

Networking and Refreshment Break

Third-Party Risk Management

15:30

PANEL DISCUSSION Risky Business —
How Third-Party Relationships Can Define Your Company’s Reputation

MODERATOR:

Robert Shropshire
Global Offering Lead
IQVIA

PANELISTS:

Chirag Vanjara
Senior Director, Regional Compliance Lead – Emerging Asia
Pfizer Asia Manufacturing Pte Ltd

Carol Wu
Director, Third Party Audit, Asia, Global Ethics & Compliance
GlaxoSmithKline

Krishantha Wirasinghe, MD
Medical Advisor
Hemas Pharmaceuticals (Pvt) Ltd.

The Marketplace —
Updates in an Evolving Regulatory Landscape

16:15

Current Environment of Drug Promotion in Japan

The Japanese government is recently giving closer look on the drug promotion through its monitoring program and the promotional guidelines released in September 2018 (effective in April 2019). The session will provide an update on current and future practices across the pharmaceutical industry under the Guidelines.

Kinichi Enomoto
Country Compliance Lead (Japan)
Pfizer Holdings

16:45

Life Sciences in China — Focusing on Cybersecurity Law

Carly Ramsey
Associate Director
Control Risks

17:30

Close of Day One

Networking, Wine and Cheese Reception immediately following the final session on day one

DAY TWO WEDNESDAY, 13 MARCH 2019

8:15

Continental Breakfast

8:45

Chairperson’s Review of Day One

Mike Zhao
Head of Ethics and Compliance, China
UCB

Robert Shropshire
Global Offering Lead
IQVIA

Transparency Reporting

9:00

Reporting Challenges and Opportunities Reshaping the Life Sciences

Joyce Wong
Managing Director, Polaris Asia Pacific
IQVIA

Jinyoung Kim
Legal and Compliance Lead – Korea, Taiwan and Southeast Asia
Bristol-Myers Squibb

9:45

PANEL DISCUSSION Compare Strategies for Managing Sponsorship and Promotional Risks

MODERATOR:

Amila Bewtra
IQVIA Commercial Compliance Account Lead
IQVIA Commercial Compliance

PANELISTS:

Justus Chua
Head of Legal and Compliance
Boehringer Ingelheim

Krishantha Wirasinghe, MD
Medical Advisor
Hemas Pharmaceuticals (Pvt) Ltd.

Kinichi Enomoto
Country Compliance Lead (Japan)
Pfizer Holdings

10:45

Networking and Refreshment Break

HCP Risk Management

11:15

Five Employee Corruption Schemes You Should Be Aware Of

Brian Burke
Partner
Shearman & Sterling LLP

12:00

Networking Luncheon

Asia-Pacific Competition Law

13:00

CASE STUDY Internal Investigations and Compliance Program Remediation

Jonathan Shun Wah
Assistant General Counsel – Greater China & APAC, Investigations Lead
Pfizer

Data Analytics

13:45

CASE STUDY New Initiatives and Related Challenges — Implementing a
Compliance Monitoring Program and Whistleblowing Hotline

Aki Sudo
Director, Compliance
Otsuka Pharmaceutical Co., Ltd.

14:30

Close of Conference

Want more agenda details? Download the brochure.

DAY ONE TUESDAY, 12 MARCH 2019

8:00

Registration and Continental Breakfast

8:30

Co-Chairs’ Welcome and Opening Remarks

Mike Zhao
Head of Ethics and Compliance, China
UCB

Robert Shropshire
Global Offering Lead
IQVIA

Ethics and Compliance in Business Decision-Making

8:45

PANEL DISCUSSION Building a Culture of Ethics and Integrity to Ensure Corporate Compliance

MODERATOR:

Justus Chua
Head of Legal and Compliance
Boehringer Ingelheim

PANELISTS:

Hussein Al-Shawaf
Compliance & Ethics Manager
Dentsply Sirona

Clarissa Shen
Vice President, China Head of Ethics and Business Integrity
Sanofi

Hiroyuki Fukumori
Director, Corporate Compliance
Taiho Pharmaceutical Co., Ltd.

Kinichi Enomoto
Country Compliance Lead (Japan)
Pfizer Holdings

9:45

Future-Proofing Your China Strategy and Business Operations

Neal Beatty
Partner
Control Risks

10:30

Networking and Refreshment Break

11:00

CASE STUDY Key Indicators to Measure the Value and Performance of a
Compliance Program

Christine Ng
Head, Ethics & Compliance Officer, Greater China
GlaxoSmithKline

11:45

Asia Pacific Life Sciences and Compliance Survey 2018

Yvonne Wu
Deloitte China Life Sciences and Health Care Leader
Deloitte

12:30

Networking Luncheon

Anti-Bribery and Anti-Corruption (ABAC)

13:30

Gain Insights from FCPA Investigations and the Changing Landscape of Global Cooperation

Tiffany R. Moseley
Partner
Loeb & Leob

14:15

Global Anti-Corruption Enforcement and Evolving Challenges for
Life Science Organizations in Asia

Eric Carlson
Partner
Covington & Burling LLP

15:00

Networking and Refreshment Break

Third-Party Risk Management

15:30

PANEL DISCUSSION Risky Business —
How Third-Party Relationships Can Define Your Company’s Reputation

MODERATOR:

Robert Shropshire
Global Offering Lead
IQVIA

PANELISTS:

Chirag Vanjara
Senior Director, Regional Compliance Lead – Emerging Asia
Pfizer Asia Manufacturing Pte Ltd

Carol Wu
Director, Third Party Audit, Asia, Global Ethics & Compliance
GlaxoSmithKline

Krishantha Wirasinghe, MD
Medical Advisor
Hemas Pharmaceuticals (Pvt) Ltd.

The Marketplace —
Updates in an Evolving Regulatory Landscape

16:15

Current Environment of Drug Promotion in Japan

The Japanese government is recently giving closer look on the drug promotion through its monitoring program and the promotional guidelines released in September 2018 (effective in April 2019). The session will provide an update on current and future practices across the pharmaceutical industry under the Guidelines.

Kinichi Enomoto
Country Compliance Lead (Japan)
Pfizer Holdings

16:45

Life Sciences in China — Focusing on Cybersecurity Law

Carly Ramsey
Associate Director
Control Risks

17:30

Close of Day One

Networking, Wine and Cheese Reception immediately following the final session on day one

DAY TWO WEDNESDAY, 13 MARCH 2019

8:15

Continental Breakfast

8:45

Chairperson’s Review of Day One

Mike Zhao
Head of Ethics and Compliance, China
UCB

Robert Shropshire
Global Offering Lead
IQVIA

Transparency Reporting

9:00

Reporting Challenges and Opportunities Reshaping the Life Sciences

Joyce Wong
Managing Director, Polaris Asia Pacific
IQVIA

Jinyoung Kim
Legal and Compliance Lead – Korea, Taiwan and Southeast Asia
Bristol-Myers Squibb

9:45

PANEL DISCUSSION Compare Strategies for Managing Sponsorship and Promotional Risks

MODERATOR:

Amila Bewtra
IQVIA Commercial Compliance Account Lead
IQVIA Commercial Compliance

PANELISTS:

Justus Chua
Head of Legal and Compliance
Boehringer Ingelheim

Krishantha Wirasinghe, MD
Medical Advisor
Hemas Pharmaceuticals (Pvt) Ltd.

Kinichi Enomoto
Country Compliance Lead (Japan)
Pfizer Holdings

10:45

Networking and Refreshment Break

HCP Risk Management

11:15

Five Employee Corruption Schemes You Should Be Aware Of

Brian Burke
Partner
Shearman & Sterling LLP

12:00

Networking Luncheon

Asia-Pacific Competition Law

13:00

CASE STUDY Internal Investigations and Compliance Program Remediation

Jonathan Shun Wah
Assistant General Counsel – Greater China & APAC, Investigations Lead
Pfizer

Data Analytics

13:45

CASE STUDY New Initiatives and Related Challenges — Implementing a
Compliance Monitoring Program and Whistleblowing Hotline

Aki Sudo
Director, Compliance
Otsuka Pharmaceutical Co., Ltd.

14:30

Close of Conference